Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts
Chad J. Creighton(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), Anna Tsimelzon(Pancreatic Cancer Action Network), Luca Malorni(Azienda Usl Toscana Centro), Jiang Shou(Breast Center), C. Kent Osborne(Baylor College of Medicine), Suleiman Massarweh(University of Kentucky), Shixia Huang(Southwest University)
Cited by 138
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k